These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 7187844)

  • 1. [Use of the dissolution test in controlling the bioavailability of solid oral pharmaceutical forms].
    Carli F; Ceriani D; Frattini C; Gorlato P; Maffione G; Moro L; Neri G; Ciranni Signoretti E
    Ann Ist Super Sanita; 1982; 18(3):551-8. PubMed ID: 7187844
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of novel ibuprofen-loaded solid dispersion with improved bioavailability using aqueous solution.
    Park YJ; Kwon R; Quan QZ; Oh DH; Kim JO; Hwang MR; Koo YB; Woo JS; Yong CS; Choi HG
    Arch Pharm Res; 2009 May; 32(5):767-72. PubMed ID: 19471892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approaches for the development of solid and semi-solid lipid-based formulations.
    Jannin V; Musakhanian J; Marchaud D
    Adv Drug Deliv Rev; 2008 Mar; 60(6):734-46. PubMed ID: 18045728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The importance of micronization in the design of dosage forms I. Theoretical and biopharmaceutical aspects].
    Antal I
    Acta Pharm Hung; 2006; 76(2):95-103. PubMed ID: 17094668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory aspects of drug dissolution from a European perspective.
    Graffner C
    Eur J Pharm Sci; 2006 Nov; 29(3-4):288-93. PubMed ID: 16950606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs.
    Vasconcelos T; Sarmento B; Costa P
    Drug Discov Today; 2007 Dec; 12(23-24):1068-75. PubMed ID: 18061887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current perspectives in dissolution testing of conventional and novel dosage forms.
    Azarmi S; Roa W; Löbenberg R
    Int J Pharm; 2007 Jan; 328(1):12-21. PubMed ID: 17084051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.
    Blagden N; de Matas M; Gavan PT; York P
    Adv Drug Deliv Rev; 2007 Jul; 59(7):617-30. PubMed ID: 17597252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fast-dissolving microparticles fail to show improved oral bioavailability.
    Wong SM; Kellaway IW; Murdan S
    J Pharm Pharmacol; 2006 Oct; 58(10):1319-26. PubMed ID: 17034654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A mini review of scientific and pharmacopeial requirements for the disintegration test.
    Donauer N; Löbenberg R
    Int J Pharm; 2007 Dec; 345(1-2):2-8. PubMed ID: 17935916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Commentary on AAPS Workshop: dissolution testing for the twenty-first century: linking critical quality attributes and critical process parameters to clinically relevant dissolution.
    Tong C; D'Souza SS; Parker JE; Mirza T
    Pharm Res; 2007 Sep; 24(9):1603-7. PubMed ID: 17385013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry.
    Pabla D; Akhlaghi F; Zia H
    Eur J Pharm Biopharm; 2009 May; 72(1):105-10. PubMed ID: 18996189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral Solid Dosage Form Disintegration Testing - The Forgotten Test.
    Al-Gousous J; Langguth P
    J Pharm Sci; 2015 Sep; 104(9):2664-75. PubMed ID: 25546430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probability of passing dissolution acceptance criteria for an immediate release tablet.
    Dumont ML; Berry MR; Nickerson B
    J Pharm Biomed Anal; 2007 May; 44(1):79-84. PubMed ID: 17379465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissolution properties of different designed and formulated salbutamol tablet dosage forms.
    Ozkan Y; Savaşer A; Ozalp Y; Işimer A
    Acta Pol Pharm; 2000; 57(4):271-6. PubMed ID: 11126615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of global regulations concerning biowaivers for immediate release solid oral dosage forms.
    Gupta E; Barends DM; Yamashita E; Lentz KA; Harmsze AM; Shah VP; Dressman JB; Lipper RA
    Eur J Pharm Sci; 2006 Nov; 29(3-4):315-24. PubMed ID: 16806858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioavailability: some pharmaceutical factors.
    Fowle AS
    Trans Med Soc Lond; 1975; 91():23-32. PubMed ID: 1236035
    [No Abstract]   [Full Text] [Related]  

  • 18. Dissolution evaluation of marketed tetracyclines solid oral dosage forms.
    Yamamoto CH; Pinto Tde J; Alves MS
    Boll Chim Farm; 2000; 139(2):81-4. PubMed ID: 10920533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Drugs and the organism. II. Bioavailability].
    Pflegel P; Pfeifer S
    Pharmazie; 1980; 34(5-6):337-59. PubMed ID: 6893363
    [No Abstract]   [Full Text] [Related]  

  • 20. In vitro - in vivo correlation: from theory to applications.
    Emami J
    J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.